bevacizumab + everolimus + liposomal doxorubicin

This is a combination regimen consisting of three agents: - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis and reducing blood supply to tumors. - **Everolimus** is an oral small molecule inhibitor of the mammalian target of rapamycin (mTOR), which disrupts cell growth, proliferation, and survival by inhibiting the PI3K/AKT/mTOR pathway. - **Liposomal doxorubicin** is an anthracycline chemotherapy agent encapsulated in liposomes for improved delivery and reduced toxicity; it intercalates DNA and generates free radicals to induce tumor cell death. The combination has been investigated primarily in breast cancer—especially triple-negative breast cancer (TNBC) with resistance to standard neoadjuvant chemotherapy—and other solid tumors. The rationale for this regimen is to simultaneously inhibit tumor angiogenesis (bevacizumab), block key intracellular signaling pathways involved in tumor survival (everolimus), and directly kill dividing cells via cytotoxic chemotherapy (liposomal doxorubicin)[1][4][5].

Other names

bevacizumab plus everolimus plus liposomal doxorubicinDAE